Page last updated: 2024-10-25

citalopram and Cardiovascular Stroke

citalopram has been researched along with Cardiovascular Stroke in 14 studies

Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.

Research Excerpts

ExcerptRelevanceReference
"To investigate the effect on long-term major adverse cardiac events (MACE) of escitalopram treatment of depression in patients with recent ACS."9.27Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JH; Kim, JM; Kim, JW; Kim, MC; Kim, SW; Lee, HJ; Lee, YS; Shin, IS; Stewart, R; Yoon, JS, 2018)
"TALOS is an investigator-initiated, national multicenter randomized- and placebo-controlled, double-blind trial testing citalopram in acute ischemic stroke."9.20TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. ( Andersen, G; Grove, EL; Johnsen, SP; Kraglund, KL; Mortensen, JK, 2015)
"To investigate the effect on long-term major adverse cardiac events (MACE) of escitalopram treatment of depression in patients with recent ACS."5.27Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JH; Kim, JM; Kim, JW; Kim, MC; Kim, SW; Lee, HJ; Lee, YS; Shin, IS; Stewart, R; Yoon, JS, 2018)
"TALOS is an investigator-initiated, national multicenter randomized- and placebo-controlled, double-blind trial testing citalopram in acute ischemic stroke."5.20TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. ( Andersen, G; Grove, EL; Johnsen, SP; Kraglund, KL; Mortensen, JK, 2015)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (35.71)29.6817
2010's9 (64.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kim, JM1
Stewart, R1
Lee, YS1
Lee, HJ1
Kim, MC1
Kim, JW1
Kang, HJ1
Bae, KY1
Kim, SW1
Shin, IS1
Hong, YJ1
Kim, JH1
Ahn, Y1
Jeong, MH1
Yoon, JS1
Kraglund, KL2
Mortensen, JK2
Damsbo, AG1
Modrau, B1
Simonsen, SA1
Iversen, HK1
Madsen, M1
Grove, EL2
Johnsen, SP2
Andersen, G2
Davidson, KW1
Burg, MM1
Carney, RM1
Freedland, KE1
Acikel, S1
Dogan, M1
Sari, M1
Kilic, H1
Akdemir, R1
Bah, TM1
Benderdour, M1
Kaloustian, S1
Karam, R1
Rousseau, G1
Godbout, R1
Labos, C1
Dasgupta, K1
Nedjar, H1
Turecki, G1
Rahme, E1
Jiang, W1
Velazquez, EJ1
Samad, Z1
Kuchibhatla, M1
Martsberger, C1
Rogers, J1
Williams, R1
Kuhn, C1
Ortel, TL1
Becker, RC1
Pristera, N1
Krishnan, R1
O'Connor, CM1
Zuidersma, M1
Conradi, HJ1
van Melle, JP3
Ormel, J3
de Jonge, P2
van den Brink, RH1
Honig, A2
Schene, AH2
Crijns, HJ1
Lambert, FP1
Pogosova, GV1
Zhidko, NI1
Mikheeva, TG1
Baĭchorov, IKh1
Sakkas, P1
Psarros, C1
Papadimitriou, GN1
Theleritis, CG1
Soldatos, CR1
Kuyper, AM1
Tulner, D1
Schins, A1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy and Safety of Escitalopram in the Treatment of Depressive Patients With Acute Coronary Artery Syndrome: A Double-blind Placebo-controlled Trial[NCT00419471]Phase 4300 participants (Actual)Interventional2007-05-31Completed
The Efficacy of Citalopram Treatment in Acute Stroke[NCT01937182]Phase 2642 participants (Actual)Interventional2013-09-30Completed
Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463]Phase 288 participants (Anticipated)Interventional2021-07-18Recruiting
Mindfulness-Based Cognitive Therapy Delivered Via Group Videoconferencing for Acute Coronary Syndrome Patients With Elevated Depression Symptoms[NCT03878160]27 participants (Actual)Interventional2018-07-01Completed
Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT Trial)[NCT00574847]Phase 4127 participants (Actual)Interventional2006-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Interpersonal Reactivity Index (IRI)

This is a 14-item scale that measures empathy. The scoring scale ranges from 0, does not describe me well, to 4, describes me very well. The score values range from 0-56, where high values represent higher levels of empathy and lower values represent lower levels of empathy. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview41
Women and Men, >2 Years, Individual Interview39
Women and Men, Lifetime History of ACS, Individual Interview45

Medical Outcomes Study - Specific Adherence Scale (MOS- SAS)

This is a 3-item scale that measures health behaviors. The scoring scale ranges from 1, none of the time, to 6, all of the time. The scoring values range from 3-18, where higher values represent good health behavior and lower values represent poor health behavior. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview11
Women and Men, >2 Years, Individual Interview10
Women and Men, Lifetime History of ACS, Individual Interview13

Patient Health Questionnaire-9 (PHQ-9)

This is a 9-item scale that measures depression. The scoring scale ranges from 0, not at all, to 3, nearly every day. The scoring values range from 0-18, where high values represent higher levels of depression and lower values represent lower levels of depression. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview10.5
Women and Men, >2 Years, Individual Interview16
Women and Men, Lifetime History of ACS, Individual Interview1.5

Patient Reported Outcome Measurement Information System-Physical Function (PROMIS-29-PF)

This is a 4-item scale that measures and evaluates physical health. The scoring scale ranges from 5, without any difficulty, to 1, unable to do. The scoring values range from 4-20, where high values represent good physical function and low values represent poor physical function. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview18
Women and Men, >2 Years, Individual Interview12
Women and Men, Lifetime History of ACS, Individual Interview20

Perceived Stress Scale-4 (PSS-4)

This is a 4-item scale that measures stress. The scoring scale ranges from 0,never, to 4, very often. The scale values range from 0-16 with higher values representing higher levels of individual stress and lower values representing lower levels of individual stress. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview12
Women and Men, >2 Years, Individual Interview14
Women and Men, Lifetime History of ACS, Individual Interview6

Positive Affect Negative Affect Schedule (PANAS)

This is a 20-question scale, composed of 2, 10-item scales that measure positive and negative affect. The scoring scale ranges from 1, very slightly or not at all, to 5, extremely. For this study, we will only use the positive affect sub-scale. The scale values for the positive affect sub-scale range from 10-50. Higher values on the positive affect scale represent higher levels of positive affect, whereas, lower values on the negative affect scale represent lower levels of positive affect. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview22
Women and Men, >2 Years, Individual Interview26
Women and Men, Lifetime History of ACS, Individual Interview34

Rumination Response Scale (RRS)

This is a 22-item scale that measures rumination. The scoring scale ranges from 1,almost never, to 4, almost always. The score values range from 22 to 88, where higher values represent higher levels of rumination and lower values represent lower levels of rumination. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview41
Women and Men, >2 Years, Individual Interview51.5
Women and Men, Lifetime History of ACS, Individual Interview31

Self-Other Four Immeasurables (SOFI) Scale

This is a 16-item scale that measures views toward the self and others. This measure consists of four sub-scales with four items each. The sub-scales measure positive views toward self, negative views toward self, positive views toward others, and negative views toward other. Only the positive-other sub-scale was used. The scoring scale ranges from 1, very slightly or not at all to 5, extremely, with sub-scale scores ranging from 4-20. Higher values represent higher levels of positive feelings toward others, and lower values represent lower levels of positive feelings toward others. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview15
Women and Men, >2 Years, Individual Interview12.5
Women and Men, Lifetime History of ACS, Individual Interview16

Short-Form-12 (SF-12)

This is a 12-item scale that measures health-related quality of life. The scoring scale from item 1 ranges from 1, excellent to 5, poor. The scoring scale for items 2 and 3 ranges from 1, limit you a lot to 3, not limit you at all. The scoring scale for questions 5-7 is represented by 1, yes or 2, no. The scoring scale for item 8 ranges from 1, not at all, to 5, extremely. The scoring scale for items 9-11 ranges from 1, all of the time, to 6, none of the time. The scoring scale for item 12 ranges from 1, all of the time to 5, none of the time. The total scoring values range from 12- 47, where higher values represent a higher quality of life and lower values represent a lower quality of life. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

Interventionunits on a scale (Median)
Women and Men, <2 Years, Individual Interview26
Women and Men, >2 Years, Individual Interview22
Women and Men, Lifetime History of ACS, Individual Interview40

Five Factor Mindfulness Questionnaire- 15 Item (FFMQ-15)

This is a 15-item measure that measures mindfulness. This scale has five sub-scales: observing, describing, acting with awareness, accepting without judgment, and non-reactivity. The scoring scale ranges from 1, never or very rarely true to 5, very often or always true. Scale values range from 3-15 for each sub-scale, with higher values representing greater levels of individual mindfulness and lower values representing lowers levels of individual mindfulness. There is no total score for the measure; only individual sub-scales are reported. Data collection for this measurement is cross-sectional, and is collected during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session

,,
Interventionunits on a scale (Median)
ObservingDescribingActing with awarenessAccepting without judgmentNonreactivity
Women and Men, <2 Years, Individual Interview811111111
Women and Men, >2 Years, Individual Interview99989.5
Women and Men, Lifetime History of ACS, Individual Interview1013101414

Number of Participants Reporting Changes After ACS

This portion of the individual interview will focus on exploring changes experienced after an ACS, such as psychosocial changes and health behavior changes. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The identified themes are reported, and the criteria used to determine the outcome measure is the number of participants who endorsed each theme. (NCT03878160)
Timeframe: one 30-90-minute session

,,
Interventionparticipants (Number)
Positive health behavior changesAdaptive perspectivesEmotional improvementsSocial improvementsActivity limitationsNegative physical symptomsEmotional problemsSocial problemsHealth behavior challenges
Women and Men, <2 Years, Individual Interview310155332
Women and Men, >2 Years, Individual Interview301078825
Women and Men, Lifetime History of ACS, Individual Interview1051546640

Number of Participants With Perspectives on Blood Spot Data Collection

This portion of the individual interview will focus on exploring ACS patients who had perspectives on participating in a remote dried blood spot procedure. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The criteria used to determine the outcome measure is the number of participants upon interview who reported any type of perspective on participating in a remote dried blood spot procedure (self-collection of dried blood spot via finger-prick). Please note that the number of perspectives reported for each theme can exceed the number of people per group because each participant reported multiple perspectives (e.g., both pros and cons of videoconferencing). (NCT03878160)
Timeframe: one 30-90-minute session

,,
Interventionparticipants (Number)
Willing to complete DBSWould need trainingWould want more information about the rationale
Women and Men, <2 Years, Individual Interview525
Women and Men, >2 Years, Individual Interview754
Women and Men, Lifetime History of ACS, Individual Interview826

Number of Participants With Perspectives on MBCT

This portion of the individual interview will focus on exploring patients' perspectives toward an MBCT treatment approach. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The identified themes are reported, and the criteria used to determine the outcome measure is the number of participants who endorsed each theme. (NCT03878160)
Timeframe: one 30-90-minute session

,,
Interventionparticipants (Number)
Willing to get helpWilling to participate in a group programPositive reaction to mindfulness
Women and Men, <2 Years, Individual Interview334
Women and Men, >2 Years, Individual Interview867
Women and Men, Lifetime History of ACS, Individual Interview887

Number of Participants With Perspectives on Videoconferencing

This portion of the individual interview will focus on exploring perspectives regarding videoconferencing intervention delivery. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. Identified themes are reported, and the criteria used to determine the outcome measure is the number of participants upon interview who reported expressed each theme. (NCT03878160)
Timeframe: one 30-90-minute session

,,
Interventionparticipants (Number)
Willing to try videoconferencingLogistical benefitsSocial benefitsTechnology limitationsSocial limitations
Women and Men, <2 Years, Individual Interview35222
Women and Men, >2 Years, Individual Interview75151
Women and Men, Lifetime History of ACS, Individual Interview87124

5HTT, Serotonin Transporter Protein

End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: week 6

Interventionfmol/mg (Mean)
Escitalopram139.7
Placebo160.4

Beck Depression Inventory

The Beck Depression Inventory II (BDI-II) is a 21 question, self-administered measure of depressive symptoms. Score range, 0 to 63 (higher score=greater severity of depressive symptoms). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week

Interventionunits on a scale (Mean)
Escitalopram7.4
Placebo7.0

Cook-Medley Hostility (Ho) Hostile Affect Sub-scale

hostile affect, 0 to 5 (higher score=greater levels of hostile affect). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Escitalopram1.6
Placebo1.8

Cook-Medley Hostility (Ho) Scale

Score ranges: hostility, 0 to 27 (higher score=greater levels of hostility)/ End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Escitalopram9.9
Placebo10.3

Exercise Stressed-induced Myocardial Ischemia (ESIMI)

End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week

Interventionpercentage of change (Number)
Escitalopram45.8
Placebo52.5

Mental Stress Induced Change in Heart Rate

"A standard 12-lead Electrocardiograph (ECG) will be recorded at 1-minute intervals during the last 3 minutes of each rest period, the 3 minutes of the mental stress testing, and during exercise testing. Heart rate will be determined from the ECGs.~Mental Stress Induced Change in heart rate will be calculated by taking the mean of the mental stress heart rate measurements minus the resting heart rate measurements. End point values adjusted for baseline values age and sex." (NCT00574847)
Timeframe: baseline, 6 weeks

Interventionbeats/minute (Mean)
Escitalopram6.34
Placebo9.1

Mental Stress Induced Change of Diastolic Blood Pressure

Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Diastolic Blood Pressure will be calculated by taking the mean of the mental stress Diastolic blood pressure measurements minus the resting Diastolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6

Interventionmm Hg (Mean)
Escitalopram11.4
Placebo12.2

Mental Stress Induced Change of Systolic Blood Pressure

Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Systolic Blood Pressure will be calculated by taking the mean of the mental stress systolic blood pressure measurements minus the resting Systolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6

Interventionmm Hg (Mean)
Escitalopram19.3
Placebo23.6

Perceived Stress Scale

Score range, 10 to 50 (higher score = greater levels of perceived stress). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Escitalopram21.4
Placebo21.8

Percentage of Participants With Adverse Events

(NCT00574847)
Timeframe: Baseline to week 6

Interventionpercentage of participants (Number)
Escitalopram71.9
Placebo44.4

Percentage of Participants With an Absence of Mental Stress-induced Myocardial Ischemia (MSIMI) During the 3 Mental Stressors

MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: Week 6

Interventionpercentage of participants (Number)
Escitalopram34.2
Placebo17.5

Percentage of Participants With Overall Mental Stress-induced Myocardial Ischemia (MSIMI)

MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: week 6

Interventionpercentage of participants (Number)
Escitalopram66.1
Placebo83.9

Platelet Serotonin Binding Affinity Kd_100

End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

InterventionnM (Mean)
Escitalopram4202.4
Placebo210.1

Spielberger State-Trait Anxiety Inventory Scales (STAI)

STAI measures anxiety. The questionnaire asks the patients how they feel and allows them to respond on a frequency scale that ranges from 1(not at all) to 4(almost always/very much so). Scores range from 20-80 and the higher the score the greater the anxiety level. This applies to both the Trait and State scales. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks

,
Interventionunits on a scale (Mean)
TraitState
Escitalopram31.227.9
Placebo32.029.5

Reviews

1 review available for citalopram and Cardiovascular Stroke

ArticleYear
Treatment-resistant depression and mortality after acute coronary syndrome.
    The American journal of psychiatry, 2009, Volume: 166, Issue:4

    Topics: Acute Coronary Syndrome; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Therapy;

2009

Trials

8 trials available for citalopram and Cardiovascular Stroke

ArticleYear
Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial.
    JAMA, 2018, 07-24, Volume: 320, Issue:4

    Topics: Acute Coronary Syndrome; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressi

2018
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
    Stroke, 2018, Volume: 49, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi

2018
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
    Stroke, 2018, Volume: 49, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi

2018
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
    Stroke, 2018, Volume: 49, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi

2018
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
    Stroke, 2018, Volume: 49, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi

2018
TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:6

    Topics: Brain Ischemia; Citalopram; Double-Blind Method; Follow-Up Studies; Humans; Mental Status Schedule;

2015
Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.
    American heart journal, 2012, Volume: 163, Issue:1

    Topics: Adult; Cardiovascular Diseases; Citalopram; Depressive Disorder; Exercise Test; Humans; Myocardial I

2012
Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial.
    Journal of psychosomatic research, 2013, Volume: 74, Issue:1

    Topics: Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Fo

2013
Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT).
    American heart journal, 2002, Volume: 144, Issue:2

    Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Double-Blind Method; Follow-Up Studie

2002
[Clinical effectiveness and safety of citalopram in patients with depression after myocardial infarction].
    Kardiologiia, 2003, Volume: 43, Issue:1

    Topics: Adult; Aged; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Dis

2003
Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events.
    The American journal of psychiatry, 2007, Volume: 164, Issue:9

    Topics: Antidepressive Agents; Cardiovascular Diseases; Cause of Death; Citalopram; Comorbidity; Depressive

2007

Other Studies

5 other studies available for citalopram and Cardiovascular Stroke

ArticleYear
Implementing an antidepressant treatment strategy for post-MI depression does not reduce risk of further cardiovascular events or mortality.
    Evidence-based mental health, 2013, Volume: 16, Issue:3

    Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Myoc

2013
Prinzmetal-variant angina in a patient using zolmitriptan and citalopram.
    The American journal of emergency medicine, 2010, Volume: 28, Issue:2

    Topics: Angina Pectoris, Variant; Citalopram; Coronary Angiography; Coronary Vasospasm; Drug Therapy, Combin

2010
Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression.
    Behavioural brain research, 2011, Nov-20, Volume: 225, Issue:1

    Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Citalopram; Cytokines; Depr

2011
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2011, Nov-08, Volume: 183, Issue:16

    Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag

2011
Repetitive transcranial magnetic stimulation (rTMS) in a patient suffering from comorbid depression and panic disorder following a myocardial infarction.
    Progress in neuro-psychopharmacology & biological psychiatry, 2006, Volume: 30, Issue:5

    Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Citalopram; Clorazepate Dipotassium;

2006